Galmed Pharmaceuticals Stock Target Price and Analyst Consensus

GLMD Stock  USD 2.86  0.01  0.35%   
The current analyst and expert consensus on Galmed Pharmaceuticals is Buy, with no strong buy opinions. The current projected Galmed Pharmaceuticals target price consensus is 4.00 with 1 analyst opinions. Check out Macroaxis Advice on Galmed Pharmaceuticals to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.
For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.
The most common way Galmed Pharmaceuticals analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Galmed Pharmaceuticals executives and customers to further validate their buy or sell advice. Please note, the number of analysts providing the opinion is not sufficient to provide adequate consensus on Galmed Pharmaceuticals. We encourage you to use your own analysis of Galmed Pharmaceuticals to validate this buy or sell advice. Galmed Pharmaceuticals buy-or-sell recommendation module provides average expert sentiment on the projected Galmed Pharmaceuticals target price to derive its highest and lowest estimates based on projected price volatility of 37.8999.
Lowest Forecast
3.64
Highest Forecast
4.44
Target Price
4
The current year's Gross Profit is expected to grow to about (29.4 K). In addition to that, Pretax Profit Margin is expected to decline to -4.54. At present, Galmed Pharmaceuticals' Accounts Payable is projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 3.6 M, whereas Total Assets are forecasted to decline to about 15.8 M.
  
It's important to approach Galmed Pharmaceuticals' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.

Galmed Pharmaceuticals Target Price Consensus

Galmed target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Galmed Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
   One  Buy
Most Galmed analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Galmed stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Galmed Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Galmed Pharmaceuticals Target Price Projection

Galmed Pharmaceuticals' current and average target prices are 2.86 and 4.00, respectively. The current price of Galmed Pharmaceuticals is the price at which Galmed Pharmaceuticals is currently trading. On the other hand, Galmed Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Galmed Pharmaceuticals Market Quote on 2nd of December 2024

Low Price2.78Odds
High Price2.94Odds

2.86

Target Price

Analyst Consensus On Galmed Pharmaceuticals Target Price

Low Estimate3.64Odds
High Estimate4.44Odds

4.0

Historical Lowest Forecast  3.64 Target Price  4.0 Highest Forecast  4.44
Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Galmed Pharmaceuticals and the information provided on this page.

Galmed Pharmaceuticals Analyst Ratings

Galmed Pharmaceuticals' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Galmed Pharmaceuticals stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Galmed Pharmaceuticals' financials, market performance, and future outlook by experienced professionals. Galmed Pharmaceuticals' historical ratings below, therefore, can serve as a valuable tool for investors.

Analyst Consensus Breakdown

Average Consensus Estimates

Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.

Steps to utilize Galmed Pharmaceuticals price targets

Galmed Pharmaceuticals' stock target price is an estimate of its future price, usually made by analysts. Using Galmed Pharmaceuticals' target price to determine if it is a suitable investment can be done through the following steps:
  • Look at Galmed Pharmaceuticals' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
  • Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
  • Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
  • Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Galmed Pharmaceuticals' stock is likely to perform well.
  • Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Remember that stock target prices are just estimates and are subject to change. Therefore, using them as one factor in a larger investment strategy is essential rather than relying solely on them to make decisions.

Additional Galmed Pharmaceuticals Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Galmed Pharmaceuticals is a key component of Galmed Pharmaceuticals valuation and have some predictive power on the future returns of a Galmed Pharmaceuticals.
Hype
Prediction
LowEstimatedHigh
0.112.1340.03
Details
Intrinsic
Valuation
LowRealHigh
0.173.3741.27
Details
Naive
Forecast
LowNextHigh
0.073.7141.61
Details
Earnings
Estimates (0)
LowProjected EPSHigh
0.000.000.00
Details

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Macroaxis Index Idea
Macroaxis Index
Invested few shares
Online Gaming Idea
Online Gaming
Invested few shares
Disruptive Technologies Idea
Disruptive Technologies
Invested one share
Power Assets Idea
Power Assets
Invested few shares
Size And Style ETFs Idea
Size And Style ETFs
Invested few shares
Millennials Best Idea
Millennials Best
Invested one share
ESG Investing Idea
ESG Investing
Invested few shares
Rentals Idea
Rentals
Invested one share
Corona Opportunity Idea
Corona Opportunity
Invested few shares
Artificial Intelligence Idea
Artificial Intelligence
Invested few shares
Driverless Cars Idea
Driverless Cars
Invested over 200 shares
When determining whether Galmed Pharmaceuticals is a strong investment it is important to analyze Galmed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galmed Pharmaceuticals' future performance. For an informed investment choice regarding Galmed Stock, refer to the following important reports:
Check out Macroaxis Advice on Galmed Pharmaceuticals to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.
For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Please note, the presentation of Galmed Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Galmed Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Galmed Pharmaceuticals' management manipulating its earnings.